Survival Benefit of Boron Neutron Capture Therapy for Recurrent Malignant Gliomas

Overview

Journal J Neurooncol

Publisher Springer

Date 2008 Sep 25

PMID 18813875

Citations 64

Authors

Shin-Ichi Miyatake

Shinji Kawabata

Kunio Yokoyama

Toshihiko Kuroiwa

Hiroyuki Michiue

Yoshinori Sakurai

Hiroaki Kumada

Minoru Suzuki

Akira Maruhashi

Mitsunori Kirihata

Koji Ono

Affiliations

Soon will be listed here.

Abstract

We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

Citing Articles

Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness.

Punshon L, Fabbrizi M, Phoenix B, Green S, Parsons J Cells. 2025; 13(24.

PMID: 39768156 PMC: 11674336. DOI: 10.3390/cells13242065.

Current research trends and hotspots of boron neutron capture therapy: a bibliometric and visualization analysis.

Cong Y, Abulimiti M, Matsumoto Y, Jin J Front Oncol. 2024; 14:1507157.

PMID: 39726703 PMC: 11669655. DOI: 10.3389/fonc.2024.1507157.

Ultrasound Combination to Improve the Efficacy of Current Boron Neutron Capture Therapy for Head and Neck Cancer.

Yura Y, Fujita Y, Hamada M Cancers (Basel). 2024; 16(15).

PMID: 39123497 PMC: 11311392. DOI: 10.3390/cancers16152770.

Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT.

Barth R, Gupta N, Kawabata S Cancer Commun (Lond). 2024; 44(8):893-909.

PMID: 38973634 PMC: 11337926. DOI: 10.1002/cac2.12582.

Prognostic assessment of F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors.

Lin K, Chen Y, Wang L, Wang Y, Hu L, Ting C Quant Imaging Med Surg. 2024; 14(6):4177-4188.

PMID: 38846276 PMC: 11151257. DOI: 10.21037/qims-23-1769.

References

Glantz M, Burger P, Friedman A, Radtke R, Massey E, Schold Jr S . Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology. 1994; 44(11):2020-7. DOI: 10.1212/wnl.44.11.2020. View

Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K . Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery. 2007; 61(1):82-90. DOI: 10.1227/01.neu.0000279727.90650.24. View

Coderre J, CHANANA A, JOEL D, Elowitz E, Micca P, Nawrocky M . Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiat Res. 1998; 149(2):163-70. View

Brada M, Hoang-Xuan K, Rampling R, Dietrich P, Dirix L, MacDonald D . Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001; 12(2):259-66. DOI: 10.1023/a:1008382516636. View

Miyashita M, Miyatake S, Imahori Y, Yokoyama K, Kawabata S, Kajimoto Y . Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol. 2008; 89(2):239-46. DOI: 10.1007/s11060-008-9621-6. View

Sakurai Y, Ono K, Miyatake S, Maruhashi A . Improvement effect on the depth-dose distribution by CSF drainage and air infusion of a tumour-removed cavity in boron neutron capture therapy for malignant brain tumours. Phys Med Biol. 2006; 51(5):1173-83. DOI: 10.1088/0031-9155/51/5/009. View

Huncharek M, Muscat J . Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. 1998; 18(2B):1303-11. View

Veninga T, Langendijk H, Slotman B, Rutten E, van der Kogel A, Prick M . Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiother Oncol. 2001; 59(2):127-37. DOI: 10.1016/s0167-8140(01)00299-7. View

Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M . Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg. 2005; 103(6):1000-9. DOI: 10.3171/jns.2005.103.6.1000. View

10.

Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Skold K . An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand. 2008; 117(3):191-7. DOI: 10.1111/j.1600-0404.2007.00924.x. View

11.

Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K . Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res. 2008; 50(1):51-60. DOI: 10.1269/jrr.08043. View

12.

Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A . Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg. 2007; 105(6):898-903. DOI: 10.3171/jns.2006.105.6.898. View

13.

Hudes R, Corn B, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L . A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999; 43(2):293-8. DOI: 10.1016/s0360-3016(98)00416-7. View

14.

Henriksson R, Capala J, Michanek A, Lindahl S, Salford L, Franzen L . Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol. 2008; 88(2):183-91. DOI: 10.1016/j.radonc.2006.04.015. View

15.

Joensuu H, Kankaanranta L, Seppala T, Auterinen I, Kallio M, Kulvik M . Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol. 2003; 62(1-2):123-34. DOI: 10.1007/BF02699939. View

16.

Shrieve D, Alexander 3rd E, Wen P, Fine H, Kooy H, Black P . Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995; 36(2):275-82; discussion 282-4. DOI: 10.1227/00006123-199502000-00006. View

17.

Carson K, Grossman S, Fisher J, Shaw E . Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007; 25(18):2601-6. PMC: 4118746. DOI: 10.1200/JCO.2006.08.1661. View

18.

Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T . Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res. 1998; 4(8):1825-32. View

19.

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

20.

Kawabata S, Miyatake S, Kajimoto Y, Kuroda Y, Kuroiwa T, Imahori Y . The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. J Neurooncol. 2003; 65(2):159-65. DOI: 10.1023/b:neon.0000003751.67562.8e. View